Sernova Testing AgeX’s UniverCyte Technology to Deliver FVIII to Hemophilia A Patients
Sernova will use AgeX Therapeutics’ UniverCyte gene technology to create a cell-based therapy that delivers therapeutic levels of factor VIII (FVIII) — the blood clotting protein deficient in people with…